Characterisation of a LoVo subline resistant to a benzoyl mustard derivative of distamycin A (FCE 24517).

Human colon adenocarcinoma cells (LoVo) resistant to the new antitumor agent FCE 24517 [benzoyl-mustard derivative of distamycin A] (LoVo/24517) are resistant to the selecting agent and related molecules as well as to vinblastine, with marginal or no resistance to other antitumour drugs. Treatment w...

Descripción completa

Detalles Bibliográficos
Autores principales: Capolongo, L., Melegaro, G., Broggini, M., Mongelli, N., Grandi, M.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1993
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968750/
https://www.ncbi.nlm.nih.gov/pubmed/8105866
Descripción
Sumario:Human colon adenocarcinoma cells (LoVo) resistant to the new antitumor agent FCE 24517 [benzoyl-mustard derivative of distamycin A] (LoVo/24517) are resistant to the selecting agent and related molecules as well as to vinblastine, with marginal or no resistance to other antitumour drugs. Treatment with verapamil, tamoxifen, nicergoline or cyclosporin A only partially restores the activity of FCE 24517 against LoVo/24517 cells. Such results suggest that resistance mechanisms possible specific for this class of compounds are operating. IMAGES:

Ejemplares similares